Reset
Showing 16 of 16 academic articles

Sacituzumab govitecan plus toripalimab compared with toripalimab plus nab-paclitaxel for first-line treatment of unresectable, locally advanced, or metastatic triple-negative breast cancer: protocol of a multicenter, open-label, randomized phase II trial.

Zhang S, Zhao J, Ling X, Mo X et al. • Translational breast cancer research : a journal focusing on translational research in breast cancer (2026)
PMC PMC Public Access (View-Only) DOI: 10.21037/tbcr-2026-0056 PMC: PMC13736023

In silico design of a triple-negative breast cancer vaccine by targeting cancer testis antigens

Sepideh Parvizpour, Jafar Razmara, Mohammad M. Pourseif, Yadollah Omidi • BioImpacts (2019)

Introduction: Triple-negative breast cancer (TNBC) is an important subtype of breast cancer, which occurs in the absence of estrogen, progesterone and HER-2 receptors. According to the recent studies, TNBC may be a cancer testis antigen (CT...

DOAJ Open Access (DOAJ) DOI: 10.15171/bi.2019.06

Inhibiting BCKDK in triple negative breast cancer suppresses protein translation, impairs mitochondrial function, and potentiates doxorubicin cytotoxicity

Dipsikha Biswas, Logan Slade, Luke Duffley, Neil Mueller et al. • Cell Death Discovery (2021)

Proposed mechanism. A Doxorubicin (DOX) targets the BCAA catabolic pathway in TNBCs, by downregulating BCKDK and augmenting clearance of intracellular BCKAs. B Genetic or pharmacological (high BT2 concentration) inhibition of BCKDK results ...

DOAJ Open Access (DOAJ) DOI: 10.1038/s41420-021-00602-0

Evaluating key predictors of breast cancer through survival: a comparison of AFT frailty models with LASSO, ridge, and elastic net regularization

Senyefia Bosson-Amedenu, Emmanuel Ayitey, Francis Ayiah-Mensah, Luyton Asare • BMC Cancer (2025)

Abstract Background Frailty models are extensively utilized in survival analysis to address unobserved heterogeneity among individuals. However, selecting the most robust model for survival prediction, especially in the context of high-dime...

DOAJ Open Access (DOAJ) DOI: 10.1186/s12885-025-14040-z

Identification of DDIT4 as a potential prognostic marker associated with chemotherapeutic and immunotherapeutic response in triple-negative breast cancer

Xuanzhao Chen, Zeyan Li, Meihua Liang, Ziyang Zhang et al. • World Journal of Surgical Oncology (2023)

Abstract Background Triple-negative breast cancer (TNBC) is the most heterogenous and aggressive subtype of breast cancer. Chemotherapy remains the standard treatment option for patients with TNBC owing to the unavailability of acceptable t...

DOAJ Open Access (DOAJ) DOI: 10.1186/s12957-023-03078-7

Association of androgen receptor and tumour-infiltrating lymphocytes with bone recurrence in triple-negative breast cancer

Petra Ilenič, Ajda Herman, Erik Langerholc, Barbara Gazić et al. • Journal of Bone Oncology (2024)

Background: As compared to endocrine responsive breast cancer bone is less frequent site of distant recurrence in triple-negative breast cancer (TNBC). A biomarker which predicts bone recurrence would allow a more personalized treatment app...

DOAJ Open Access (DOAJ) DOI: 10.1016/j.jbo.2023.100518

Hypoxia-Inducible Expression of Annexin A6 Enhances the Resistance of Triple-Negative Breast Cancer Cells to EGFR and AR Antagonists

Stephen D. Williams, Tunde M. Smith, LaMonica V. Stewart, Amos M. Sakwe • Cells (2022)

Physiological changes such as hypoxia in the tumor microenvironment (TME) endow cancer cells with malignant properties, leading to tumor recurrence and rapid progression. Here, we assessed the effect of hypoxia (1% Oxygen) on the tumor supp...

DOAJ Open Access (DOAJ) DOI: 10.3390/cells11193007